English

SQZ BIOTECHNOLOGIES COMPANY

EDGAR

SQZ Quarterly report (10-Q) · filed 2023-11-08

16 filing records in this dataset, filed from 2020-10-09 to 2023-11-08. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2023-09-30 · USD

Exact inputs and evidence

Revenue: 178000 USD Source
Revenue: 178000 USD Source

Operating cash flow

-14.5 million USD

2023-09-30 · USD

Exact inputs and evidence

Operating Cash Flow: -53574000 USD Source
Operating Cash Flow: -39042000 USD Source

Free cash flow

-14.5 million USD

2023-09-30 · USD

Exact inputs and evidence

Operating Cash Flow: -53574000 USD Source
Operating Cash Flow: -39042000 USD Source
Capital Expenditure: 112000 USD Source
Capital Expenditure: 112000 USD Source

Cash and cash equivalents: 10.2 million USD 2023-09-30 Source
Exact value

10193000 USD
Long-term debt including current maturities: 0 USD 2019-12-31 Source
Exact value

0 USD
Shares outstanding: 29.5 million shares 2023-09-30 Source
Exact value

29491125 shares

Reported share-count change

0.48% · 141 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

29350158 shares · 2022-09-30· Source
29491125 shares · 2023-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-71.6 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Net income: -79464000 USD · 2022-01-01 – 2022-12-31 Source
Net income: -65917000 USD · 2022-01-01 – 2022-09-30 Source
Net income: -17687000 USD · 2023-01-01 – 2023-03-31 Source
Net income: -16770000 USD · 2023-04-01 – 2023-06-30 Source
Net income: -23639000 USD · 2023-07-01 – 2023-09-30 Source

Operating cash flow

-74.3 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Operating cash flow: -83549000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -62789000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -23772000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -39042000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -23772000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -53574000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -39042000 USD · 2023-01-01 – 2023-06-30 Source

Capital expenditure

213 thousand USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Capital expenditure: 522000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 421000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 65000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 112000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 65000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 112000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 112000 USD · 2023-01-01 – 2023-06-30 Source

Free cash flow

-74.5 million USD

2022-10-01 – 2023-09-30

Exact inputs and evidence

Operating cash flow: -83549000 USD · 2022-01-01 – 2022-12-31 Source
Operating cash flow: -62789000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: -23772000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -39042000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -23772000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -53574000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -39042000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 522000 USD · 2022-01-01 – 2022-12-31 Source
Capital expenditure: 421000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 65000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 112000 USD · 2023-01-01 – 2023-06-30 Source
Capital expenditure: 65000 USD · 2023-01-01 – 2023-03-31 Source
Capital expenditure: 112000 USD · 2023-01-01 – 2023-09-30 Source
Capital expenditure: 112000 USD · 2023-01-01 – 2023-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-11-08.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2022-12-31
Operating income: 5 of 11 periods available· newest 2022-12-31
Net income: 5 of 11 periods available· newest 2022-12-31
Operating cash flow: 5 of 11 periods available· newest 2022-12-31
Capital expenditure: 5 of 11 periods available· newest 2022-12-31
Total assets: 5 of 11 periods available· newest 2022-12-31
Total liabilities: 5 of 11 periods available· newest 2022-12-31
Current assets: 5 of 11 periods available· newest 2022-12-31
Current liabilities: 5 of 11 periods available· newest 2022-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2022-12-31
Long-term debt including current maturities: 2 of 11 periods available· newest 2019-12-31
Shares outstanding: 5 of 11 periods available· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-20.7%

Prior period

USD 27.1 million

2021-01-01 – 2021-12-31
Current period

USD 21.48 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

21478000 − 27098000 = -5620000 USD

27098000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
21478000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · SQZ BIOTECHNOLOGIES COMPANY · 2022-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Year-over-year change in Revenue: -5620000 USD Concept: fundies:Revenue Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 21478000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2546772 Filing: 000095017023009203 Input fundies:Revenue: 27098000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2548828 Filing: 000095017023009203
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 10.72 million

Prior period

−USD 68.74 million

2021-01-01 – 2021-12-31
Current period

−USD 79.46 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-79464000 − -68741000 = -10723000 USD

-68741000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-79464000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · SQZ BIOTECHNOLOGIES COMPANY · 2022-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Year-over-year change in Net income: -10723000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -79464000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#3809604 Filing: 000095017023009203 Input fundies:NetIncome: -68741000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#3811850 Filing: 000095017023009203
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.41 million

Prior period

−USD 82.14 million

2021-01-01 – 2021-12-31
Current period

−USD 83.55 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-83549000 − -82137000 = -1412000 USD

-82137000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-83549000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · SQZ BIOTECHNOLOGIES COMPANY · 2022-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Year-over-year change in Operating cash flow: -1412000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -83549000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2836615 Filing: 000095017023009203 Input fundies:OperatingCashFlow: -82137000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2838978 Filing: 000095017023009203
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-14.8%

Prior period

USD 613,000

2021-01-01 – 2021-12-31
Current period

USD 522,000

2022-01-01 – 2022-12-31

Exact inputs and evidence

522000 − 613000 = -91000 USD

613000 USD · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
522000 USD · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · SQZ BIOTECHNOLOGIES COMPANY · 2022-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Year-over-year change in Capital expenditure: -91000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 522000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2844702 Filing: 000095017023009203 Input fundies:CapitalExpenditure: 613000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2846884 Filing: 000095017023009203
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2022-01-01 – 2022-12-31

Revenue USD 21.48 million 100% of revenue
Operating costs Derived USD 102.16 million 476% of revenue
Operating income −USD 80.68 million −376% of revenue
Tax, interest and other Derived −USD 1.22 million −5.7% of revenue
Net income −USD 79.46 million −370% of revenue

Cash

Operating cash flow −USD 83.55 million −389% of revenue
Capital expenditure USD 522,000 2.4% of revenue
Free cash flow Derived −USD 84.07 million −391% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Operating loss: operating costs were 261% of revenue.
2019 Operating loss: operating costs were 270% of revenue.
2020 Operating loss: operating costs were 343% of revenue.
2021 Operating loss: operating costs were 354% of revenue.
2022 Operating loss: operating costs were 476% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	12669000	33073000 Derived	-20404000	-1154000 Derived	-19250000	19792000 Derived	Source 2018-01-01 – 2018-12-31: 12669000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -20404000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -19250000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: 21097000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 1305000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	20109000	54374000 Derived	-34265000	-2063000 Derived	-32202000	-35659000 Derived	Source 2019-01-01 – 2019-12-31: 20109000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -34265000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -32202000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -33491000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 2168000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	20998000	72056000 Derived	-51058000	-537000 Derived	-50521000	-44328000 Derived	Source 2020-01-01 – 2020-12-31: 20998000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -51058000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -50521000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -43151000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1177000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	27098000	95867000 Derived	-68769000	-28000 Derived	-68741000	-82750000 Derived	Source 2021-01-01 – 2021-12-31: 27098000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -68769000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -68741000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -82137000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 613000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	21478000	102162000 Derived	-80684000	-1220000 Derived	-79464000	-84071000 Derived	Source 2022-01-01 – 2022-12-31: 21478000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -80684000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -79464000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -83549000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 522000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 21.5M 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	12669000	Revenue: 12669000 Open source
20192019-12-31	Revenue	20109000	Revenue: 20109000 Open source
20202020-12-31	Revenue	20998000	Revenue: 20998000 Open source
20212021-12-31	Revenue	27098000	Revenue: 27098000 Open source
20222022-12-31	Revenue	21478000	Revenue: 21478000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-20.7% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 12669000 Open source
20192019-12-31	Year over year	58.7%	Revenue: 20109000 Open source Revenue: 12669000 Open source
20202020-12-31	Year over year	4.4%	Revenue: 20998000 Open source Revenue: 20109000 Open source
20212021-12-31	Year over year	29.1%	Revenue: 27098000 Open source Revenue: 20998000 Open source
20222022-12-31	Year over year	-20.7%	Revenue: 21478000 Open source Revenue: 27098000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -375.7% 2022

Net margin -370% 2022

Free cash flow margin -391.4% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	-161.1%	Operating Income: -20404000 Open source Revenue: 12669000 Open source
20192019-12-31	Operating margin	-170.4%	Operating Income: -34265000 Open source Revenue: 20109000 Open source
20202020-12-31	Operating margin	-243.2%	Operating Income: -51058000 Open source Revenue: 20998000 Open source
20212021-12-31	Operating margin	-253.8%	Operating Income: -68769000 Open source Revenue: 27098000 Open source
20222022-12-31	Operating margin	-375.7%	Operating Income: -80684000 Open source Revenue: 21478000 Open source
20182018-12-31	Net margin	-151.9%	Net Income: -19250000 Open source Revenue: 12669000 Open source
20192019-12-31	Net margin	-160.1%	Net Income: -32202000 Open source Revenue: 20109000 Open source
20202020-12-31	Net margin	-240.6%	Net Income: -50521000 Open source Revenue: 20998000 Open source
20212021-12-31	Net margin	-253.7%	Net Income: -68741000 Open source Revenue: 27098000 Open source
20222022-12-31	Net margin	-370%	Net Income: -79464000 Open source Revenue: 21478000 Open source
20182018-12-31	Free cash flow margin	156.2%	Revenue: 12669000 Open source Operating Cash Flow: 21097000 Open source Capital Expenditure: 1305000 Open source
20192019-12-31	Free cash flow margin	-177.3%	Revenue: 20109000 Open source Operating Cash Flow: -33491000 Open source Capital Expenditure: 2168000 Open source
20202020-12-31	Free cash flow margin	-211.1%	Revenue: 20998000 Open source Operating Cash Flow: -43151000 Open source Capital Expenditure: 1177000 Open source
20212021-12-31	Free cash flow margin	-305.4%	Revenue: 27098000 Open source Operating Cash Flow: -82137000 Open source Capital Expenditure: 613000 Open source
20222022-12-31	Free cash flow margin	-391.4%	Revenue: 21478000 Open source Operating Cash Flow: -83549000 Open source Capital Expenditure: 522000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -83.5M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	21097000	Operating Cash Flow: 21097000 Open source
20192019-12-31	Operating cash flow	-33491000	Operating Cash Flow: -33491000 Open source
20202020-12-31	Operating cash flow	-43151000	Operating Cash Flow: -43151000 Open source
20212021-12-31	Operating cash flow	-82137000	Operating Cash Flow: -82137000 Open source
20222022-12-31	Operating cash flow	-83549000	Operating Cash Flow: -83549000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -84.1M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	19792000	Operating Cash Flow: 21097000 Open source Capital Expenditure: 1305000 Open source
20192019-12-31	Free cash flow	-35659000	Operating Cash Flow: -33491000 Open source Capital Expenditure: 2168000 Open source
20202020-12-31	Free cash flow	-44328000	Operating Cash Flow: -43151000 Open source Capital Expenditure: 1177000 Open source
20212021-12-31	Free cash flow	-82750000	Operating Cash Flow: -82137000 Open source Capital Expenditure: 613000 Open source
20222022-12-31	Free cash flow	-84071000	Operating Cash Flow: -83549000 Open source Capital Expenditure: 522000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

42.8% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Liabilities / assets	45.6%	Total Liabilities: 52686000 Open source Total Assets: 115547000 Open source
20192019-12-31	Liabilities / assets	61.5%	Total Liabilities: 93756000 Open source Total Assets: 152350000 Open source
20202020-12-31	Liabilities / assets	45%	Total Liabilities: 103942000 Open source Total Assets: 231141000 Open source
20212021-12-31	Liabilities / assets	45.2%	Total Liabilities: 102176000 Open source Total Assets: 226152000 Open source
20222022-12-31	Liabilities / assets	42.8%	Total Liabilities: 42752000 Open source Total Assets: 99900000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.12× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Current assets / current liabilities	5.1×	Current Assets: 108813000 Open source Current Liabilities: 21330000 Open source
20192019-12-31	Current assets / current liabilities	2.66×	Current Assets: 101818000 Open source Current Liabilities: 38283000 Open source
20202020-12-31	Current assets / current liabilities	3.91×	Current Assets: 176831000 Open source Current Liabilities: 45193000 Open source
20212021-12-31	Current assets / current liabilities	4.53×	Current Assets: 150635000 Open source Current Liabilities: 33224000 Open source
20222022-12-31	Current assets / current liabilities	3.12×	Current Assets: 68204000 Open source Current Liabilities: 21843000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2018 2018-01-01 – 2018-12-31	−USD 19.25 million Exact value Exact value: -19250000 USD 2018-01-01 – 2018-12-31: -19250000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SQZ BIOTECHNOLOGIES COMPANY · 2018-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Net Income: -19250000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19250000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000119312521034349/sqz-20200930.xml#2434888 Filing: 000119312521034349 The citation records this snapshot. The page link may show a newer release later.	USD 21.1 million Exact value Exact value: 21097000 USD 2018-01-01 – 2018-12-31: 21097000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SQZ BIOTECHNOLOGIES COMPANY · 2018-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Operating Cash Flow: 21097000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 21097000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000119312521034349/sqz-20200930.xml#778952 Filing: 000119312521034349 The citation records this snapshot. The page link may show a newer release later.	USD 1.31 million Exact value Exact value: 1305000 USD 2018-01-01 – 2018-12-31: 1305000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SQZ BIOTECHNOLOGIES COMPANY · 2018-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Capital Expenditure: 1305000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1305000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000119312521034349/sqz-20200930.xml#779363 Filing: 000119312521034349 The citation records this snapshot. The page link may show a newer release later.	USD 19.79 million Calculation and evidence 21097000 − 1305000 USD Exact free cash flow: 19792000 USD 2018-01-01 – 2018-12-31: 21097000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 1305000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SQZ BIOTECHNOLOGIES COMPANY · 2018-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Free cash flow: 19792000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 21097000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000119312521034349/sqz-20200930.xml#778952 Filing: 000119312521034349 Input fundies:CapitalExpenditure: 1305000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000119312521034349/sqz-20200930.xml#779363 Filing: 000119312521034349 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 32.2 million Exact value Exact value: -32202000 USD 2019-01-01 – 2019-12-31: -32202000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SQZ BIOTECHNOLOGIES COMPANY · 2019-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Net Income: -32202000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32202000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000156459021013996/sqz-20201231.xml#179012 Filing: 000156459021013996 The citation records this snapshot. The page link may show a newer release later.	−USD 33.49 million Exact value Exact value: -33491000 USD 2019-01-01 – 2019-12-31: -33491000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SQZ BIOTECHNOLOGIES COMPANY · 2019-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Operating Cash Flow: -33491000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33491000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000156459021013996/sqz-20201231.xml#201571 Filing: 000156459021013996 The citation records this snapshot. The page link may show a newer release later.	USD 2.17 million Exact value Exact value: 2168000 USD 2019-01-01 – 2019-12-31: 2168000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SQZ BIOTECHNOLOGIES COMPANY · 2019-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Capital Expenditure: 2168000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2168000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000156459021013996/sqz-20201231.xml#201993 Filing: 000156459021013996 The citation records this snapshot. The page link may show a newer release later.	−USD 35.66 million Calculation and evidence -33491000 − 2168000 USD Exact free cash flow: -35659000 USD 2019-01-01 – 2019-12-31: -33491000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 2168000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SQZ BIOTECHNOLOGIES COMPANY · 2019-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Free cash flow: -35659000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33491000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000156459021013996/sqz-20201231.xml#201571 Filing: 000156459021013996 Input fundies:CapitalExpenditure: 2168000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000156459021013996/sqz-20201231.xml#201993 Filing: 000156459021013996 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 50.52 million Exact value Exact value: -50521000 USD 2020-01-01 – 2020-12-31: -50521000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SQZ BIOTECHNOLOGIES COMPANY · 2020-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Net Income: -50521000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50521000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017022003930/sqz-20211231.htm#3638973 Filing: 000095017022003930 The citation records this snapshot. The page link may show a newer release later.	−USD 43.15 million Exact value Exact value: -43151000 USD 2020-01-01 – 2020-12-31: -43151000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SQZ BIOTECHNOLOGIES COMPANY · 2020-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Operating Cash Flow: -43151000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -43151000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017022003930/sqz-20211231.htm#2709372 Filing: 000095017022003930 The citation records this snapshot. The page link may show a newer release later.	USD 1.18 million Exact value Exact value: 1177000 USD 2020-01-01 – 2020-12-31: 1177000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SQZ BIOTECHNOLOGIES COMPANY · 2020-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Capital Expenditure: 1177000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1177000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017022003930/sqz-20211231.htm#2716490 Filing: 000095017022003930 The citation records this snapshot. The page link may show a newer release later.	−USD 44.33 million Calculation and evidence -43151000 − 1177000 USD Exact free cash flow: -44328000 USD 2020-01-01 – 2020-12-31: -43151000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1177000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SQZ BIOTECHNOLOGIES COMPANY · 2020-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Free cash flow: -44328000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -43151000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017022003930/sqz-20211231.htm#2709372 Filing: 000095017022003930 Input fundies:CapitalExpenditure: 1177000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017022003930/sqz-20211231.htm#2716490 Filing: 000095017022003930 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 68.74 million Exact value Exact value: -68741000 USD 2021-01-01 – 2021-12-31: -68741000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SQZ BIOTECHNOLOGIES COMPANY · 2021-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Net Income: -68741000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -68741000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#3811850 Filing: 000095017023009203 The citation records this snapshot. The page link may show a newer release later.	−USD 82.14 million Exact value Exact value: -82137000 USD 2021-01-01 – 2021-12-31: -82137000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SQZ BIOTECHNOLOGIES COMPANY · 2021-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Operating Cash Flow: -82137000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -82137000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2838978 Filing: 000095017023009203 The citation records this snapshot. The page link may show a newer release later.	USD 613,000 Exact value Exact value: 613000 USD 2021-01-01 – 2021-12-31: 613000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SQZ BIOTECHNOLOGIES COMPANY · 2021-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Capital Expenditure: 613000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 613000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2846884 Filing: 000095017023009203 The citation records this snapshot. The page link may show a newer release later.	−USD 82.75 million Calculation and evidence -82137000 − 613000 USD Exact free cash flow: -82750000 USD 2021-01-01 – 2021-12-31: -82137000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 613000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SQZ BIOTECHNOLOGIES COMPANY · 2021-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Free cash flow: -82750000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -82137000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2838978 Filing: 000095017023009203 Input fundies:CapitalExpenditure: 613000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2846884 Filing: 000095017023009203 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 79.46 million Exact value Exact value: -79464000 USD 2022-01-01 – 2022-12-31: -79464000 USD Inspect Net Income Open source Share or cite Citation for Net Income · SQZ BIOTECHNOLOGIES COMPANY · 2022-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Net Income: -79464000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -79464000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#3809604 Filing: 000095017023009203 The citation records this snapshot. The page link may show a newer release later.	−USD 83.55 million Exact value Exact value: -83549000 USD 2022-01-01 – 2022-12-31: -83549000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · SQZ BIOTECHNOLOGIES COMPANY · 2022-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Operating Cash Flow: -83549000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -83549000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2836615 Filing: 000095017023009203 The citation records this snapshot. The page link may show a newer release later.	USD 522,000 Exact value Exact value: 522000 USD 2022-01-01 – 2022-12-31: 522000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · SQZ BIOTECHNOLOGIES COMPANY · 2022-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Capital Expenditure: 522000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 522000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2844702 Filing: 000095017023009203 The citation records this snapshot. The page link may show a newer release later.	−USD 84.07 million Calculation and evidence -83549000 − 522000 USD Exact free cash flow: -84071000 USD 2022-01-01 – 2022-12-31: -83549000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 522000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · SQZ BIOTECHNOLOGIES COMPANY · 2022-12-31 SQZ BIOTECHNOLOGIES COMPANY (edgar:1604477) Free cash flow: -84071000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1604477?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -83549000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2836615 Filing: 000095017023009203 Input fundies:CapitalExpenditure: 522000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1604477/000095017023009203/sqz-20221231.htm#2844702 Filing: 000095017023009203 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

16 filings · 1,075 latest values · 1,075 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001604477, 1604477, SQZ, SQZB, edgar:1604477

Also known as SQZ BIOTECHNOLOGIES COMPANY, SQZ Biotechnologies Co

SQZ BIOTECHNOLOGIES COMPANY

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2022-01-01 – 2022-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation